Details

Autor(en) / Beteiligte

• Ashton, Nicholas J
• Janelidze, Shorena
• Al Khleifat, Ahmad
• Leuzy, Antoine
• van der Ende, Emma L
• Karikari, Thomas K
• Benedet, Andrea L
• Pascoal, Tharick A
• Lleó, Alberto
• Parnetti, Lucilla
• Galimberti, Daniela
• Bonanni, Laura
• Pilotto, Andrea
• Padovani, Alessandro
• Lycke, Jan
• Novakova, Lenka
• Axelsson, Markus
• Velayudhan, Latha
• Rabinovici, Gil D
• Miller, Bruce
• Pariante, Carmine
• Nikkheslat, Naghmeh
• Resnick, Susan M
• Thambisetty, Madhav
• Schöll, Michael
• Fernández-Eulate, Gorka
• Gil-Bea, Francisco J
• López de Munain, Adolfo
• Al-Chalabi, Ammar
• Rosa-Neto, Pedro
• Strydom, Andre
• Svenningsson, Per
• Stomrud, Erik
• Santillo, Alexander
• Aarsland, Dag
• van Swieten, John C
• Palmqvist, Sebastian
• Zetterberg, Henrik
• Blennow, Kaj
• Hye, Abdul
• Hansson, Oskar

Titel

A multicentre validation study of the diagnostic value of plasma neurofilament light

Ist Teil von

• Nature communications, 2021-06, Vol.12 (1), p.3400-3400, Article 3400

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King's College London (n = 805) and the Swedish BioFINDER study (n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.